← Eichor
Condition: Her2 Positive Advanced Gastric Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Positive Advanced Gastric Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
Phase 3 · 286 location(s) · AstraZeneca · NCT07431281First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric
Phase 1/Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07334431Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy
Phase 1/Phase 2 · 1 location(s) · Kangbuk Samsung Hospital · NCT05640830IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05872295To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Phase 2/Phase 3 · 2 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT06504732Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06650332A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Phase 3 · 1 location(s) · Astellas Pharma Global Development, Inc. · NCT07673887HER-2 B Cell Peptide Vaccine
Phase 1 · 1 location(s) · Pravin T.P Kaumaya · NCT06414733Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer
Phase N/A · 1 location(s) · Yonsei University · NCT06767449Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Phase 2 · 1 location(s) · Peking University · NCT06023758IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT07025889A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Phase 3 · 249 location(s) · Astellas Pharma Global Development, Inc. · NCT06901531Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · 19 location(s) · Yuhan Corporation · NCT05523947SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06123494Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03740256A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastri
Phase 2 · 8 location(s) · Yu jiren · NCT05715931A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 102 location(s) · DualityBio Inc. · NCT05150691A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal
Phase 3 · 208 location(s) · Shanghai Henlius Biotech · NCT06532006Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · 250 location(s) · Daiichi Sankyo · NCT06731478A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocar
Phase N/A · 76 location(s) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT05993234KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Phase 2/Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT05427383
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.